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Abstract: Background: The European Working Group on Sarcopenia has recently proposed revised
cut-off values for the definition of low grip strength (EWGSOP2). We therefore compared performance
of the EWGSOP2 cut-off definition of low grip strength with other internationally used cut-off points
in a sample of older patients. Methods: We analyzed geriatric assessment data in a cross-sectional
sample of 98 older patients admitted to a post-acute care hospital. First, we compared prevalence
of sarcopenia and frailty phenotype in our sample using low grip strength cut-points from the
EWGSOP2 and seven other internationally used consensus statements. Second, we calculated
correlations between low grip strength and two independent surrogate outcomes (i.e., gait speed,
and the clinical frailty scale) for the EWGSOP2 and the other seven cut-point definitions. Results:
Prevalence of sarcopenia based on the EWGSOP2 grip strength cut-off values was significantly
lower (10.2%) than five of the seven other cut-point definitions (e.g., 19.4% based on Sarcopenia
Definitions and Outcomes Consortium (SDOC) criteria). Similarly, frailty phenotype prevalence
was significantly lower based on EWGSOP2 cut-points (57.1%) as compared to SDOC (70.4%).
The correlation coefficient of gait speed with low grip strength based on EWGSOP2 cut-points
was lower (0.145) as compared to other criteria (e.g., SDOC 0.240). Conclusions: Sarcopenia and
frailty phenotype were identified considerably less using the EWGSOP2 cut-points for low grip
strength, potentially underestimating prevalence of sarcopenia and frailty phenotype in post-acute
hospital patients.
Keywords: post-acute care; rehabilitation; geriatric; muscle strength; gait speed; fried phenotype;
clinical frailty scale; cut-off value
1. Introduction
Sarcopenia and physical frailty are clinical syndromes occurring in older patients
associated with adverse outcomes such as mobility impairment, fracture, functional im-
pairment, and mortality [1,2]. Prior evidence shows that both sarcopenia and frailty are
common in older inpatients (42% and 33%) and often even overlap due to similar etiological
pathways [3]. It is therefore important to identify sarcopenia and frailty in older patients
for implementing targeted interventions to prevent adverse clinical outcomes.
In the diagnostic work-up of sarcopenia, frailty grip strength is a core determinant as
a proxy measurement for overall muscle strength. In the latest guidelines of the European
Working Group on Sarcopenia in Older People (EWGSOP2), low grip strength is the
primary parameter together with low muscle mass to diagnose sarcopenia [4]. Similarly,
low grip strength is one of the five criteria, along with shrinking, exhaustion, slowness,
and low activity, for defining the Fried frailty phenotype [5].
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The EWGSOP2 consensus statement proposes new cut-points for defining low grip
strength [4]. These cut-points are higher than those defined by the EWGSOP1 published
in 2010 [6] and higher than other internationally used cut-points, including the most re-
cent cut-points recommended by the Sarcopenia Definitions and Outcomes Consortium
(SDOC) [7] in 2020 after the EWGSOP2 was published. Moreover, the Asia Working Group
on Sarcopenia (AWGS) [8,9], the Foundation for the National Institutes of Health Biomark-
ers Consortium Sarcopenia Project (FNIH) [10,11], and the Fried definition [5] proposed
different cut-off points of low grip strength. To provide an overview, we summarized
these seven internationally used definitions of low grip strength and their corresponding
derivation studies in Table 1.
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Abbreviations: N.r., not reported; YOP, year of publication; AWGS, Asia Working Group on Sarcopenia; EWGSOP, European Working
Group on Sarcopenia in Older People; FNIH, The Foundation for the National Institutes of Health Biomarkers Consortium Sarcopenia
Project; SDOC, Sarcopenia Definitions and Outcomes Consortium; SD, standard deviation; W, women; M, men; ROC, receiver operating
curve. (a) Detailed specification by the authors: “Because the additional value of including BMI in the definition of weakness was unclear
(ie, including BMI did not consistently improve model fit or result in stronger associations between weakness and slowness), we elected to
use cutpoints based on grip strength alone as our primary analysis.”
The wide range of different published cut-points is confusing, given the importance of
grip strength in the diagnosis of sarcopenia and identification of physical frailty. Therefore,
using the EWGSOP2 cut-points of low grip strength instead of using other cut-points
could have an impact on the prevalence of patients identified with sarcopenia and frailty.
However, we were unable to find any studies that have systematically compared detection
rates for sarcopenia and frailty between published grip strength cut-points. It is unclear,
how many patients with sarcopenia and frailty would be overlooked depending on what
cut-point of low grip strength is used.
The purpose of this study was to determine how the EWGSOP2 cut-points for low
grip strength compared to other internationally used cut-points perform for identifying
sarcopenia and frailty phenotype in a sample of older patients in a post-acute care hospital.
2. Materials and Methods
We conducted a retrospective analysis of cross-sectional anonymized assessment
data of patients admitted to a Geriatric Rehabilitation Hospital in Bern, Switzerland,
between November and December 2019. Standard geriatric assessments were conducted
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for all patients upon admission. The assessments were performed by clinically trained
assessors (two medical students in their last semester before graduation) using standardized
assessment forms. We excluded 9 patients who had a contraindication for muscle mass
measurement by bioelectrical impedance analyses (implantable cardioverter defibrillator or
pacemaker), leaving a total sample of 98 patients (65.7% female, mean age 84 years (sd 5.8))
included in the analysis.
Our study project was approved by the Ethics Committee in Bern, Switzerland (Req-
2020-00125). In accordance to regulations on research projects of health-related data of
human beings in Switzerland we analyzed anonymized data. While researchers do work
with health-related data of human beings, the data can no longer be assigned to the specific
individual.
2.1. Sarcopenia and Frailty Assessment
On admission, patients were assessed for sarcopenia and frailty. The assessment of
sarcopenia was based on the EWGSOP2 consensus guidelines [4] and included measure-
ment of appendicular skeletal muscle mass, grip strength, and gait speed. Appendicular
skeletal muscle mass was measured upon admission using bioelectrical impedance analysis
(BIACORPUS RX 4004M, MEDI CAL HealthCare GmbH). Low muscle mass was defined
according to the EWGSOP2 gender-specific cut-off definitions of the appendicular skeletal
muscle mass index (women < 5.5 kg/m2, men < 7 kg/m2) [4].
Grip strength was assessed in an upright sitting position using the Martin vigorimeter.
The test was performed 3 times using the dominant hand, with a 30 s interval between each
measurement. Patients were instructed to firmly squeeze the balloon for three seconds.
The maximum score of the 3 measures was used for analysis. Scores were converted from
kPa to kg using the conversion table by Neumann et al. [15].
Gait speed was measured using a standardized protocol of a 4m walk test [16,17].
Patients were instructed to walk 4 m (standing start, manual timing) at their usual speed.
The test was repeated twice with a rest time of 30 s in between and the best of the two
consecutive measurements was used for analysis. Patients were allowed to use an assistive
device (e.g., walking cane, frame), however, if the patient had limited mobility capacity
(<10 m walking distance without aid) or needed personal assistance, gait speed was
recorded as 0 m/s.
Frailty was assessed using Fried’s frailty phenotype [5]. The frailty phenotype classi-
fies older people as frail based on five characteristics (i.e., shrinking, low activity, fatigue,
slowness, weakness). Scoring definitions for each characteristic are shown in the Supple-
mental Information. A score ≥ 3 out of 5 is considered positive for the frailty phenotype.
The clinical frailty scale (CFS), another measure of frailty not including measurement of
grip strength, was also completed for each patient according to the definition by Rockwood
et al. [18]. The CFS is an ordinal scale ranging from 1 (least frail) to 9 (most frail).
2.2. Low Grip Strength Cut-Points
In addition to the EWGSOP2, we identified low grip strength cut-points from seven
other consensus definitions of sarcopenia and frailty phenotype. These included (listed in
alphabetic order):
(1) Asia Working Group for Sarcopenia (AWGS1) [8].
(2) Asia Working Group for Sarcopenia (AWGS2) [9].
(3) European Working Group on Sarcopenia in Older People 1 (EWGSOP1) [6].
(4) The Foundation for the National Institutes of Health Biomarkers Consortium Sarcope-
nia Project 1 (FNIH 1) [10].
(5) The Foundation for the National Institutes of Health Biomarkers Consortium Sarcope-
nia Project 2 (FNIH 2) [11].
(6) Fried frailty phenotype (Fried) [5].
(7) Sarcopenia Definitions and Outcomes Consortium, (SDOC) [7].
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2.3. Statistical Analyses
Study population characteristics from admission data are presented by absolute and
relative frequencies or by mean with standard deviation (sd) for categorical and continuous
variables, respectively. Power analysis was based on prior evidence expecting prevalence
of sarcopenia of 20% in older patients in a post-acute care setting [19]. At a two-sided
confidence level of 0.05, the sample size of 98 patients yields a precision of +/− 8% [20]. Mc-
Nemar testing was used to compare prevalence of sarcopenia and frailty phenotype using
the EWGOSP2 cut-off definitions of low grip strength versus the other cut-off definitions
of low grip strength. Adjusted p-values (q-value) of McNemar tests using the Hochberg
method were calculated to account for multiple pairwise comparisons. The decision to not
perform statistical comparisons among subgroups of patients to avoid type I and II error
inflation was made a priori. To assess convergent validity, we investigated correlations
between different low grip strength cut-point with independent outcomes of sarcopenia
(gait speed) and frailty (clinical frailty scale (CFS)). The point biserial correlation coefficient
was calculated to analyze correlation of prevalence of low grip strength based on cut-off
definitions (binary variables) with gait speed (continuous variable) and CFS (ordinal scale).
All analyzes were computed using Stata Version 16.0 (StataCorp LLC, College Station, TX,
USA). An adjusted p-value of <0.05 was considered statistically significant.
3. Results
3.1. Prevalence of Low Grip Strength, Sarcopenia, and Frailty Phenotype
The overall and gender-specific clinical characteristics of the sample are summarized
in Table 2.
Table 2. Study population characteristics (n = 98).
Overall Women Men










Weight, mean (sd) (kg) 70.2 (15.6) 66.6 (15.1) 77.6 (14.1)
Height, mean (sd) (cm) 163.7 (8.9) 160.0 (6.6) 171.4 (8.2)
BMI, mean (sd) (kg/m2) 26.2 (5.4) 26.0 (5.7) 26.4 (4.8)
Multimorbidity index (a), median (IQR) 18 (16–21) 17.5 (15–20) 20 (17–21.5)
Functional independence measure (FIM) (b)
median (IQR)
83.5 (69–94) 85.5 (70–95) 81.5 (69–92.5)
Number of medications, mean (sd) 11.6 (5.4) 11.4 (5.4) 12.0 (5.3)
CFS scale, median (IQR) 5 (5–6) 5 (4–6) 6 (5–7)
Gait speed, mean (sd) (m/s) 0.33 (0.28) 0.34 (0.30) 0.30 (0.23)
Frailty phenotype characteristics
Shrinking, n (%) 85 (86.7%) 59 (89.4%) 26 (81.3%)
Exhaustion, n (%) 27 (27.6%) 15 (22.7%) 12 (37.5%)
Low activity, n (%) 34 (34.7%) 24 (36.4%) 10 (31.3%)
Slowness, n (%) 94 (95.9%) 62 (93.9%) 32 (100.0%)
Sarcopenia characteristics
Low muscle mass 31 (31.6%) 20 (30.3%) 11 (34.4%)
Abbreviations: sd, standard deviation; BMI, body mass index; CFS, clinical frailty scale; IQR, interquartile range;
(a) Cumulative Illness Rating Scale (CIRS). Higher values indicate higher degree of multimorbidity; (b) higher
values indicate higher degree of functional independence.
The prevalence of low grip strength, sarcopenia, and frailty phenotype calculated
using the EWGSOP2 cut-off and for each of the other seven cut-off definitions of low grip
strength is compared in Table 3.
Overall, the EWGSOP2 cut-off value yielded the lowest prevalence of low grip strength
(27.6%), while the SDOC cut-off definition yielded the highest prevalence (56.1%). All
cut-off definitions, except for those used by the AWGS1 and FNIH1, showed statistically
significant higher prevalence of low grip strength compared with the EWGSOP2 cut-off
definition (p < 0.01).
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Prevalence of sarcopenia based on the EWGSOP2 cut-points of low grip strength
was significantly lower than those based on the SDOC, FNIH2, and EWGSOP1 defini-
tions (Table 3). Similarly, frailty phenotype prevalence was significantly lower using the
EWGSOP2 cut-off values compared with SDOC, FNIH2, and EWGSOP1 cut-off definitions.
Table 3. Prevalence of low grip strength, sarcopenia, and frailty phenotype based on EWGSOP2 cut-off definition of low









(b) Frailty Phenotype (d)
n (%) p-Value
(b)
EWGSOP2 Women <16 kgMen <27 kg 27 (27.6%) Ref 10 (10.2%) Ref 56 (57.1%) Ref
AWGS1 Women < 18 kgMen <26 kg 32 (32.7%) 0.12 10 (10.2%) 1.00 56 (57.1%) 1.00
AWGS2 Women <18 kgMen <28 kg 37 (37.8%) <0.01 12 (12.2%) 0.47 59 (60.2%) 0.25
EWGSOP1 Women <20 kgMen <30 kg 45 (45.9%) <0.01 18 (18.4%) 0.02 64 (65.3%) 0.02
FNIH1 Women <16 kgMen <26 kg 26 (26.5%) 0.32 9 (9.2%) 0.63 55 (56.1%) 0.63
FNIH2 Women <19.99 kgMen <31.83 kg 50 (51.0%) <0.01 19 (19.4%) 0.02 67 (68.4%) <0.01
Fried Women ≤17 to ≤21kg
(a)
Men ≤29 to ≤32 kg (a)
41 (41.8%) <0.01 13 (13.3%) 0.33 62 (63.3%) 0.06
SDOC Women <20 kgMen <35.5 kg 55 (56.1%) <0.01 19 (19.4%) 0.02 69 (70.4%) <0.01
Abbreviations: AWGS, Asia Working Group for Sarcopenia; SDOC, Sarcopenia Definitions and Outcomes Consortium; EWGSOP, European
Working Group on Sarcopenia in Older People; FNIH, The Foundation for the National Institutes of Health Biomarkers Consortium
Sarcopenia Project; Ref, Referent. (a) Detailed cut-off value according to gender and BMI: Women BMI≤ 23: ≤17 kg; BMI 23.1–26: ≤17.3;
BMI 26.1-29: ≤18 kg; BMI >29 kg: ≤21 kg. Men BMI ≤24: ≤29 kg; BMI 24.1–26: ≤30 kg; BMI 26.1–28: ≤30 kg; BMI >28: ≤32 kg.
(b) McNemar test comparing proportions of each grip strength definition versus EWGSOP2 grip strength definition, adjusted for multiple
pairwise testing (q-value) using the Hochberg method. (c) Sarcopenia is defined as low grip strength (using the indicated cut-off definition)
and low muscle mass (using the gender-specific cut-off value for low muscle mass according to EWGSOP2). (d) Fried frailty phenotype
according to definition in Methods section.
Gender-specific prevalence of low grip strength, sarcopenia, and frailty phenotype is
outlined in Table 4. Prevalence of sarcopenia ranged from 9.4 to 28.1% in men, whereas in
women prevalence ranged from 9.1 to 15.2%. This section may be divided by subheadings.
It should provide a concise and precise description of the experimental results, their
interpretation, as well as the experimental conclusions that can be drawn.
Table 4. Prevalence of low grip strength, sarcopenia, and frailty phenotype based on EWGSOP2 cut-off definition of low




Definition Women (n = 66)









EWGSOP2 Women <16 kgMen <27 kg 16 (24.2%) 6 (9.1%) 37 (56.1%) 11 (34.4%) 4 (12.5%) 19 (59.4%)
AWGS1 Women <18 kgMen <26 kg 22 (33.3%) 7 (10.6%) 38 (57.6%) 10 (31.3%) 3 (9.4%) 18 (56.3%)
AWGS2 Women <18 kgMen <28 kg 22 (33.3%) 7 (10.6%) 38 (57.6%) 15 (46.9%) 5 (15.6%) 21 (65.6%)
EWGSOP1 Women <20 kgMen <30 kg 26 (39.4%) 10 (15.2%) 40 (60.6%) 19 (59.4%) 8 (25.0%) 24 (75.0%)
FNIH1 Women <16 kgMen <26 kg 16 (24.2%) 6 (9.1%) 37 (56.1%) 10 (31.3%) 3 (9.4%) 18 (56.3%)
FNIH2 Women <20 kgMen <31.8 kg 26 (39.4%) 10 (15.2%) 40 (60.6%) 24 (75.0%) 9 (28.1%) 27 (84.4%)
Fried
Women
≤17 to ≤21 kg (d)
Men ≤29 to ≤32 kg (d)
22 (33.3%) 6 (9.1%) 38 (57.6%) 19 (59.4%) 7 (21.9%) 24 (75.0%)
SDOC Women <20 kgMen <35.5 kg 26 (39.4%) 10 (15.2%) 40 (60.6%) 29 (90.6%) 9 (28.1%) 29 (90.6%)
Abbreviations: SDOC, Sarcopenia Definitions and Outcomes Consortium; AWGS; Asia Working Group on Sarcopenia; EWGSOP, European
Working Group on Sarcopenia in Older People; FNIH, The Foundation for the National Institutes of Health Biomarkers Consortium
Sarcopenia Project. (a) Statistical testing of subgroups is not performed to avoid type-I and –II error inflation. (b) Sarcopenia is defined as
low grip strength (using the indicated cut-off definition) and low muscle mass (using the gender-specific cut-off value for low muscle
mass according to EWGSOP2). (c) Fried frailty phenotype according to definition in Methods section. (d) Cut-points of low grip strength
dependent on body mass index (Women BMI ≤23: ≤17 kg; BMI 23.1–26: ≤17.3; 26.1–29: ≤18 kg; >29 kg: ≤21 kg; Men BMI ≤24: <=29 kg;
BMI 24.1–26: ≤30 kg; BMI 26.1–28: ≤30 kg; BMI >28: ≤32 kg).
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3.2. Correlations with Surrogate Outcomes
Table 5 displays correlations between different low grip strength cut-points with
independent outcomes of sarcopenia (gait speed) and frailty (CFS). The correlation of gait
speed with CFS based on EWGSOP2 was lower (0.167) than correlations with low grip
strength based on the other criteria (e.g., SDOC 0.257). The cut-off definition based on
EWGSOP2 showed the lowest correlation with gait speed (0.145) compared with the other
cut-off definitions.
Table 5. Correlation coefficients (r) of cut-off definitions of low grip strength with clinical frailty scale
(CFS) and gait speed (n = 98).









Abbreviations: CFS, clinical frailty scale; AWGS; Asia Working Group on Sarcopenia; EWGSOP, European
Working Group on Sarcopenia in Older People; FNIH, The Foundation for the National Institutes of Health
Biomarkers Consortium Sarcopenia Project; SDOC, Sarcopenia Definitions and Outcomes Consortium. (a) Positive
correlation coefficients (r) indicate low grip strength correlating with frailty on the CFS (ordinal scale). (b)
Correlation coefficients (r) were reversed to enable better reading: Positive correlation coefficients indicate low
grip strength correlating with slower gait speed (continuous scale).
4. Discussion
We found that within a sample of post-acute hospital patients, the prevalence estimates
of sarcopenia and frailty phenotype based on the EWGSOP2 cut-off definition of low grip
strength were significantly lower than estimates obtained from other recommended cut-off
definitions. These results suggest that the EWGSOP2 cut-off definition of low grip strength
potentially underestimates prevalence of sarcopenia and frailty phenotype.
To our knowledge, this is the first study comparing cut-off definitions of low grip
strength to define prevalence of sarcopenia and frailty phenotype. A previous study [21]
investigated the effect of the EWGSOP2 consensus on prevalence of sarcopenia in a sample
of older inpatients, but did not compare the impact of the grip strength cut-off definitions
on sarcopenia prevalence. After applying the EWGSOP2 and the EWGSOP1 criteria to their
study sample, van Ancum et al. [21] found lower prevalence of sarcopenia with the newer
consensus recommendations. The authors concluded that the EWGSOP2 cut-off values for
low grip strength may fail to identify patients with low physical performance and/or low
muscle mass. Reiss et al. [22] found that concordance rates of individual cases of sarcopenia
were low between EWGSOP1 and EWGSOP2. Another study did not focus on EWGSOP
criteria, but compared other cut-off definitions of low grip strength demonstrating that
different cut-off definitions of low grip strength result in different proportions of people
identified with low grip strength [23]. However, this study [23] did not investigate the
impact of cut-off definitions of low grip strength on prevalence of sarcopenia and frailty
phenotype. Finally, Bertschi et al. applied EWGSOP2 consensus in sample older inpatients
to obtain prevalence of sarcopenia, but did not investigate prevalence of sarcopenia using
other definitions [19].
Our findings that the EWGSOP2 cut-off definition of low grip strength had a lower
correlation with gait speed and CFS than other recommended cut-points is another impor-
tant finding. Gait speed used as an independent surrogate of sarcopenia, is considered
a key measure in the frame of sarcopenia and is even used as a criterion for diagnosis
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of sarcopenia in some consensus definitions [9,11,24]. The relevance of gait speed in the
frame of sarcopenia is underlined by the fact that several cut-off levels of grip strength
(SDOC, FNIH1, FNIH2) were derived from a model best predicting gait speed. Recently,
the Sarcopenia Definition and Outcomes Consortium panel even agreed that both weak-
ness defined by low grip strength and slowness defined by low usual gait speed should
be included in the definition of sarcopenia [24]. This conclusion was based on a study
showing that both muscle weakness and slowness are associated with incident fall, hip
fracture, and mobility limitation [25]. The other surrogate measure used for frailty, the
CFS, is recognized as a frailty measure independent of grip strength being used in multiple
settings and being associated with clinical adverse outcomes [26].
Therefore, the low correlation coefficients of EWGSOP2 cut-points of low grip strength
that we found in our study suggest that EWGSOP2 cut-off definitions of low grip strength
may have limited validity for identifying cases of sarcopenia and frailty compared with
the other cut-off definitions of low grip strength.
Interpretation of these results is challenging because there is no gold standard for
identifying patients with true sarcopenia or true frailty. Consequently, we cannot make
a conclusive statement about which cut-off definition is most valid to detect sarcopenia
and frailty. Nevertheless, our results showing higher convergent validity of SDOC than
EWGSOP2 suggest that the use of the SDOC and other similar cut-off definitions more
accurately reflect the true prevalence of sarcopenia and frailty in older adult patients.
The lower prevalence rates associated with the EWGSOP2 are most likely due to
different methodologies used by studies to derive cut-off points. There is substantial
variation between the derivation studies with regard to study populations, how grip
strength was measured (e.g., type of device, number of trials, dominant vs. non-dominant
hand) and methods for determination of cut-points. EWGSOP2 used a similar approach
for derivation of cut-off that is known for the definition of osteoporosis, setting the cut-
off at −2.5 SD below the gender-specific mean. In contrast, the SDOC and FNIH based
their cut-off for low grip strength on a model best predicting slow walking speed in an
older population. This was also the approach used for the EWGSOP1 cut-off definition.
EWGSOP2 proposed the lowest cut-off points of low grip strength for both men and
women, resulting in low prevalence of sarcopenia and frailty. Similarly, van Ancum et al.
concluded that setting the cut-off of low grip strength at −2.5 SD may account for lower
prevalence of sarcopenia based on EWGSOP2 [21]. Nevertheless, it remains unclear what
derivation approach is best for defining cut-points that consequently lead to the most
accurate and valid definition of sarcopenia and frailty.
Subgroup analyses in our study suggest that men demonstrate higher prevalence
rates of both frailty and sarcopenia. In our study population, male patients tended to
show higher degrees of multimoribidity and polypharmacy, suggesting a generally greater
disease burden compared to female patients. Thus, general health status may account for
the higher prevalence of sarcopenia and frailty that we observed among men [27].
4.1. Limitations
Our study has several limitations. First, our study focused only on how variability in
grip strength cut-points impacted the prevalence of sarcopenia and frailty phenotype in
one sample of post-acute hospital patients. Other methodological issues associated with
measurement of grip strength measurement (e.g, type of device, instructions, selected hand,
number of trials, result used for analysis) could also affect prevalence [28]. Second, we
did not investigate the impact of other criteria (e.g., muscle mass, shrinking) used for the
overall diagnostic work-up of sarcopenia and frailty phenotype. However, we believe that
our findings of investigating the impact of one specific aspect—cut-off choice for low grip
strength—may contribute to a basis for future consensus definitions. Third, while it is
possible that we omitted other cut-off definitions of low grip strength in our comparisons
to the EWGSOP2 definition, it is unlikely that these omissions would substantially change
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our finding that the EWGSOP2 cut-point yields lower prevalence of low grip strength
compared to other definitions.
4.2. Implications
Our results have both clinical and research implications. Our results demonstrate that
the selection of a cut-off point for defining low grip strength has a clinically relevant impact
on identification of sarcopenia and frailty phenotype. The EWGSOP2 recommended cut-off
for low grip strength results in lower prevalence of sarcopenia and frailty compared with
various other internationally used cut-off definitions of low grip strength. Correlation
analyses of our data suggest limited validity of EWGSOP2 cut-off definition of low grip
strength for identifying sarcopenia and frailty phenotype. Therefore, clinicians should be
aware of the fact that patients with an actual sarcopenia or frailty phenotype are potentially
overlooked by applying the EWGSOP2 cut-points of low grip strength.
Further research is needed to clarify which cut-off values of low grip strength are
adequate for identifying cases of sarcopenia and frailty phenotype in older patients. Ideally
for practical use, cut-off values of low grip strength would be the same for the diagnostic
work-up of both sarcopenia and frailty phenotypes. Since concepts of sarcopenia as an ICD
relevant diagnosis and frailty phenotype as a clinical syndrome are different, it is possible
that different cut-off values are preferable for sarcopenia and frailty phenotype. Therefore,
interventional and longitudinal studies are needed to identify and agree on a valid cut-off
of low grip strength in the context of sarcopenia and frailty phenotype.
5. Conclusions
The selection of a cut-point of low grip strength has a clinically relevant impact on
the prevalence of sarcopenia and frailty phenotypes. Applying the EWGSOP2 cut-points
potentially results in underestimation of actual sarcopenia and frailty phenotype compared
with various other cut-off values of low grip strength.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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